Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 58, Issue 4, 1998, Pages 353-360

  Clauson, P G ^a,b   Brismar, K ^b   Hall, K ^b   Linnarsson, R ^c   Grill, V ^b  

^a NOVO NORDISK A S   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Kronan Primary Health Care Centre   (Sweden)

Author keywords

Diabetes treatment; Insulin like growth factor binding protein 1; Insulin like growth factor I; Non insulin dependent diabetes mellitus

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; COHORT ANALYSIS; DIET; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STATISTICS; SWEDEN;

EID: 0031877056     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365519850186544     Document Type: Article

References (47)

1. Boulware S, Tamborlane W, Sherwin R. Effects of IGF-I on carbohydrate and lipid metabolism. Diabetes Rev 1995; 3: 199-205.
2. Bang P, Hall K. Insulin-like growth factors as endocrine and paracrine hormones. In: Schofield P, editor The insulin-like growth factors: structures and biological function. Oxford: Oxford University Press, 1992: 151-77.
3. Brismar K, Hilding A, Lindgren B. Regulation of IGFBP-1 in humans. Progr Growth Factor Res 1995; 6: 449-56.
4. Baxter R, Martin J, Beniac V. High molecular weight insulin-like growth factor binding protein complex. J Biol Chem 1989; 264: 11842-8.
5. Cohen P, Fielder P, Hasegawa Y, Frisch H. Guidice L, Rosenfeld R. Clinical aspects of insulin-like growth factor binding proteins. Acta Endocrinol (Copenh) 1991; 124: 74-85.
6. Brismar K, Hall K. Clinical application if IGFBP-1 and its regulation. Growth Regul 1993: 98-100.
7. Baxter R, Cowell C. Diurnal rhythm of growth hormone-independent binding protein for insulin-like growth factors in human plasma. J Clin Endocrinol Metab 1987; 65: 432-40.
8. Hilding K, Brismar M, Degerblad M, Thorén M, Hall K. Altered relation between circulation levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 1995; 80: 2646-52.
9. Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. The effect of insulin on the hepatic secretion of IGFBP-1, IGFBP-3 and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 1994; 79: 872-8.
10. Lindgren B, Isaksson M, Stern I, Hall K. Insulin-like growth factor binding protein-1 from Hep G2 cells is potently inhibited by the truncated IGF-I analogue des-(1-3) IGF-I. Acta Endocrinol 1993; 128: 81-7.
11. Powell A, Suwanchkil M, Cubbage L, Paolis D, Snuggs M, Lee P. Insulin inhibits transcription of the human gene for insulin-like growth factor binding protein-1. J Biol Chem 1991: 18868-76.
12. Fernquist-Forbes J, Wahren A, Hilding A, Brismar K. Circulating epinephrine stimulates the secretion of IGFBP-1 in humans. Abstract. Growth Regul 1994; 4 Suppl 1: 92.
13. Hilding A, Brismar K, Thorén M, Hall K. Glucagon stimulates insulin-like growth-factor binding protein-1 secretion in healthy subjects, patients with pituitary insufficiency, and patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1142-7.
14. Lewitt M, Baxter R. Inhibitors of glucose uptake stimulate the production of insulin-like growth factor binding protein (IGFBP-1) by human fetal liver. Endocrinology 1990; 126: 1527-33.
15. Hall K, Lundin G, Póvoa G. Serum levels of the low molecular weight form of insulin-like growth factor binding protein in healthy subjects and patients with growth hormone deficiency, acromegaly and anorexia nervosa. Acta Endocrinol (Copenh) 1988; 118: 321-6.
16. Bang P, Brismar K, Rosenfeld R, Hall K. Fasting affects serum insulin-like growth factors (IGFs) and IGF binding proteins differently in patients with NIDDM versus healthy non-obese and obese, weight-matched subjects. J Clin Endocrinol Metab 1994; 78: 960-7.
17. Clemmons D. Insulin-like growth factor binding proteins. Trends Endocrinol Metab 1990: 412-17.
18. Lindgren B, Odar-Cederlöf I, Ericsson F, Brismar K. Decreased bioavailability of insulin-like growth factor-I, a cause of catabolism in hemodialysis patients? Growth Regul 1996; 6: 137-43.
19. Nygren J, Sammann M, Malm M, Efendic S, Hall K, Brismar K, et al. Disturbed anabolic hormonal pattern in burned patients - the relation to glucagon. Clin Endocrinol 1995; 43: 491-500.
20. Hong Y, Pedersen N, Brismar K, Hall K U, d. Faire. Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins. J Clin Endocrinol Metab 1996; 81: 1791-7.
21. Rajkumar K, Barron D, Lewitt M, Murphy L. Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. Endocrinology 1995; 136: 4029-34.
22. Thissen J, Davenport M, Pucilowska J, Miles M, Underwood L. Increased serum clearance and degradation of 1251-labeled IGF-I in protein-restricted rats. Endocrinol Metab 1992: E408-11.
23. Hall K, Johansson B, Povoa G, Thalme B. Serum levels of insulin-like growth factor (IGF)I, II and IGF binding protein in diabetic adolescents treated with continuous subcutaneous insulin infusion. J Int Med 1989; 225: 273-8.
24. Taylor A, Dunger D, Preece M. The growth hormone independent insulin-like growth factor-I binding protein BP28 is associated with serum insulin-like growth factor-I inhibitory bioactivity in adolescent insulin-dependent diabetes. Clin Endocrinol 1990; 32: 229-39.
25. Brismar K, Gutniak M, Povoa G, Werner S, Hall K. Insulin regulates the 35 KDa IGF binding protein in patients with diabetes mellitus. J Intern Med 1988; 11: 599-602.
26. Gibson J, West wood M, Crosby S, Gordon C, Holly J, Fraser W, et al. Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-1 in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1995; 80: 1369-75.
27. Clauson P, Linnarsson R, Gottsäter A, Sundkvist G, Grill V. Relationships between diabetes duration, metabolic control and b-cell function in a representative population of type 2 diabetic patients in Sweden. Diabetes Med 1994; 11: 794-801.
28. Linnarsson R. Development and evaluation of a complete computer-based problem-orientated medical record system for primary care. MIE (Medical Informatics Europe) 87 Proceedings 1987: 209-14.
29. Barnett G. The application of computer-based medical record systems in ambulatory care. N Engl J Med 1984; 310: 1643-50.
30. Webster S, Morgan M, Barnett G. Medical query language: improved access to MUMPS databases. Proceedings of the 11th Annual Symposium on Computer Application in Medical Care, Wahington 1987: 306-9.
31. Tridner P. Determination of glucose in blood using glucose oxidase with an alternative oxygen receptor. Ann Clin Biochem 1969; 6: 24-7.
32. Jeppsson J, Jerntorp P, Sundkvist G, Englund H, Nylund V. Measurement of hemoglobin A1c by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated. Clin Chem 1986; 32: 1867-72.
33. v. Rijn H, Hoekstra J, Thijssen J. Evaluation of three commercially available C-peptide kits. Ann Clin Biochem 1982; 19: 368-73.
34. Koskinen P. Nontransferability of C-peptide measurements with various commercial radioimmunoassay reagents. Clin Chem 1988; 8: 1575-8.
35. Herbert V, Lau K, Gottlieb C, Bleicher S. Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 1965; 25: 1375-84.
36. Bang P, Eriksson U, Sara V, Wirall I-L, Hall K. Comparison of acid ethanol extraction and acid gel nitration prior to IGF-I and and -II radioimmunoassays: improvement of determinations in acid ethanol extractions by use of truncated IGF-I as radioligand. Acta Endocrinol 1991; 124: 620-9.
37. Povoa G, Rodvete A, Hall K. Cross-reaction of serum somatomedin binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol 1984; 107: 563-7.
38. Alberti K, Gries F. Management of non-insulin-dependent diabetes mellitus in Europe: a consensus view. Diabetic Med 1988: 5.
39. Cerasi E, Luft R. "What is inherited - what is added" hypothesis for the pathogenesis of diabetes mellitus. Diabetes 1967; 16: 615-27.
40. DeFronzo R, Ferranini E. Insulin resistance, a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.
41. Cerasi E. Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Diabetologia 1995; 38; 992-7.
42. Efendic S, Luft R, Wajngot A. Aspects of the pathogenesis of type 2 diabetes. Endocrinol Rev 1984; 5: 395-410.
43. Midthjell K, Bjorndal A, Holmen J, Kruger O, Bjartveit K. Prevalence of known and previously unknown diabetes mellitus and impaired glucose tolerance in an adult Norwegian population. Indications of an increasing diabetes prevalence. The Nord-Trondelag Diabetes Study. Scand J Prim Health Care 1995; 13: 229-35.
44. Eriksson J, Forsen B, Haggblom M, Teppo AM, Groop L. Clinical and metabolic characteristics of type 1 and type 2 diabetes: an epidemiological study from the Narpes community in western Finland. Diabetes Med 1992; 9: 654-60.
45. Sartor G. Prevalence of type 2 diabetes in Sweden. Acta Endocrinol 1984; Suppl 262: 27-9.
46. v. Gaal L, Vansant G, v. Acker K, d. Leeuw I. Decreased hepatic insulin extraction in upper body obesity: relationship to unbound androgens and sex hormone binding globulin. Diabetes Res Clin Pract 1991; 12: 99-106.
47. Faloona G, Linger R. In:. Jaffe B, Behrman H, editors. Glucagon. New York: Academic Press, 1974: 317-30.